OTS - Series A financing round lays foundation for international growth of digital cancer therapeutics Mika (part 2)
2022. May 09. 11:49
Berlin/Lausanne/Barcelona/Munich, 9 May, 2022 (APA/OTS) -
About Fosanis
Founded in 2017 by Dr Gandolf Finke and Dr Jan Simon Raue, the
digital health company Fosanis GmbH pursues the objective of
empowering people affected by cancer with the aid of digital
technology. To this end, Fosanis GmbH has developed the AI-powered
DTx Mika in collaboration with leading oncological research
institutions and cancer centres such as the University of Leipzig
Medical Center and Charité Berlin. An app-based platform with
clinically proven efficacy, Mika became the first and hitherto only
'digital health application' (DiGA) approved for all cancer
patients in 2021. Mika is a personalised digital therapeutic (DTx)
platform in oncology. Accompanying people affected by cancer over
the course of their disease and therapy, Mika combines AI-powered
monitoring and coaching, including scientifically tested methods
and therapy management techniques. Daily check-ups - so-called
ePROs = electronic patient-reported outcomes - allow continuous
tracking of distress levels and symptoms, while a personalised
coaching programme provides scientifically validated multi-media
elements and psychooncological interventions. These include over
800 rigorously validated articles, videos and coping skills
training courses - ranging from nutrition recommendations to
physical exercise training and mindfulness coaching.
Fosanis is based in Berlin and employs more than 40 people.
Further information can be found on www.mitmika.de and
www.mikahealth.com
About Debiopharm Innovation Fund
Debiopharm develops, manufactures and invests in innovative
therapies and technologies that respond to high unmet medical needs
in oncology and bacterial infections. Debiopharm Innovation Fund
aims to provide strategic funding and guidance for companies with
Smart Data & Digital Health solutions with the ambition to change
the way drugs are developed and the way patients are treated. Our
growing portfolio company achievements include 18 FDA clearances or
CE marks and 2 IPOs along with 3 successful exits from mergers &
acquisitions. Since 2018 Debiopharm has invested over USD 150
million, leading the investment rounds of 22 of the past 30
investments. For more information, please visit www.debiopharm.com
About Ship2B Ventures
Ship2B Ventures is a venture capital firm that invests in the
best impact startups. As impact investors they seek to generate
triple profitability: economic, social and environmental. Ship2B
Ventures combine the best of the venture capital world with the
impact world, maximizing the financial profitability of their
investments with a clear intention to generate, manage and measure
their impact. Currently, the investment team has managed 60 million
€ and has participated in more than 25 investment rounds. Qida,
Psious, CodeOp or Rosita Longevity are startups invested by Ship2B
Ventures. For more information, please visit www.ship2bventures.com
About EquityPitcher Ventures
EquityPitcher is an early-growth Venture Capital firm that
supports promising startups from the DACH region. Through close
cooperation with renowned industry experts, investors and exit
partners, we pave the way for entrepreneurs to attain the three
decisive success factors: capital, know-how and network. For more
information, please visit www.equitypitcher.com
About Ananda Ventures
Ananda Impact Ventures is the leading impact venture capital
fund with a Europe-wide investment mandate. Ananda manages €180
million in four core impact funds and is backed by renowned
institutional and private investors. Ananda funds technology
companies that address the most pressing social and environmental
challenges of our time in a scalable and sustainable way. Its
active portfolio includes IESO Digital Health (online
psychotherapy), Klim (regenerative agriculture) and Ororatech
(which uses satellite technology to fight forest fires). For more
information on Ananda Impact Ventures, please visit www.ananda.vc
Note to the Editor: If desired, we will gladly connect you with
company founders Dr Gandolf Finke and Dr Jan Simon Raue.
Press contact Mika
The Medical Network
E-Mail: mika@themedicalnetwork.de
Tel. 040 32 90 47 38 99
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.